Dendreon a BUY Amid Restructuring

This article was placed on behalf of the U.S. based equity research effort of institutional broker and investment bank Canaccord Genuity. It was part of a series of articles developed under an agreement with forbes.com to work with a variety of contributors and assist them in delivering actionable investment ideas each week. The site, forbes.com is one of the top 500 sites in the world with nearly 10 million subscribers and approximately 100 million page views a month.

In a note to investors on Friday morning, Canaccord Genuity life sciences analyst George Farmer, Ph.D. reiterated his BUY rating on shares of Dendreon.

Recently Dendreon has announced a 500 employee workforce reduction and the departure of chief operating officer Hans Bishop.

Dr. Farmer said, “The company’s report of 16% monthly Provenge sales growth still implies headwinds, but affirms value of the Provenge asset, in our view and justify our BUY rating and $19 price target.

Provenge developed by Dendreon, is a treatment for prostrate cancer.

“Longer term, we see DNDN becoming cash flow positive during the first half of 2014. In addition, we see financing risk significantly mitigated and sufficient cash build to support repayment of $540 million in debt due 2016.”

Amazon Summits A Dow That No Longer Exists

At the end of February Walgreen’s Boots Alliance was unceremoniously removed from the vaunted Dow Jones Industrial Index and Amazon

Financial Institutions Feeling the Crunch in Countdown to CECL Implementation

I was retained by Big Four accounting and consulting firm KPMG to assist them in their thought leadership efforts centered on changing accounting regulations. In this case, the Financial Accounting Standards Board or FASB had instituted new rules on the measurement of current and expected credit losses, i.e. CECL, that would require massive reorganization of financial reporting for the largest financial services organizations in the world. This thought leadership piece concerned the results of a survey among C-suite executives about their state of preparedness in the final countdown to the CECL implementation.

Securitizing Structured Settlement Payment Streams: A Primer

Fall 2012. This article was written with Stefano Sola and Phil Donahue, executives at JGWPT Holdings. We were engaged by JGWPT to assist them
in publishing the article below for The Journal Of Structured Finance.

Is The Media Biased?

This story is from our February 2024 update newsletter that offers communications insights, and hopefully, some amusing diversion.

David R. Evanson, LLC